UNSPSC 51201819: Sargramostim

This classification denotes a therapeutic granulocyte-macrophage colony-stimulating factor with the molecular formula C639H1006N168O196S8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5TAA004E22, more generally known as sargramostim. European Medicines Agency schedules sargramostim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10450MIG. The term SARGRAMOSTIM is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 6, no, 3 1992, list 32.

UNSPSC 51201819 Sargramostim (Commodity) does not align with the recent state and local procurement activity tagged under it. The only recorded opportunity — a July 2026 sole source notice from the Mississippi State Department of Health — seeks Yellow Fever Vaccine from Sanofi Pasteur, not sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor used in oncology and hematology treatment. The code shows little relevant recent activity, and the mismatch between the code's nominal scope and the actual solicitation suggests either a data-entry error in the opportunity record or inconsistent code assignment by the issuing body.

The Mississippi State Department of Health posted the sole source notice on July 13, 2026, with objections due August 3, 2026 at 10:00 a.m. CST, directed to Cynthia Brasher at Cynthia.brasher@msdh.ms.gov. The notice does not specify quantity, contract term, estimated value, or pricing. Any entity believing an alternative vendor can supply the vaccine may submit written objection with detailed supporting documentation; if the department receives substantiated objections, it will conduct a competitive bid process or appeal to the Public Procurement Review Board, which requires the department to demonstrate sole-source justification.